Description: argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include Efgartigimod (ARGX-113) that completed Phase II clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy; and Cusatuzumab (ARGX-110), which is in Phase I/II clinical trials for the treatment of acute myeloid leukemia and T-cell lymphoma. It is also developing ARGX-117 for the treatment of severe autoimmune diseases; ARGX-111 to treat solid tumors; ARGX-112 to treat dermatologic indications; ARGX-115, a cancer immunotherapy-focused product candidate against the glycoprotein A repetitions predominant; ARGX-116 for the treatment of dyslipidemia; and ARGX-109 for the treatment of rheumatoid arthritis. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Cilag GmbH International; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Home Page: www.argenx.com
Willemstraat 5
Breda,
4811 AH
Netherlands
Phone:
31 10 703 8441
Officers
| Name | Title |
|---|---|
| Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc., MSc | CEO & Exec. Director |
| Prof. Hans de Haard Ir, Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. Karl Gubitz | Chief Financial Officer |
| Mr. R. Keith Woods | Chief Operating Officer |
| Mr. Arjen Lemmen M.Sc. | VP of Corp. Devel. & Strategy |
| Dr. David L. Lacey M.D. | Advisor |
| Ms. Andria Wilk | Global Head of Quality |
| Mr. Filip Borgions | VP & Global Head of Technical Operations |
| Ms. Beth DelGiacco | VP and Global Head of Corp. Communications & Investor Relations |
| Ms. Malini Moorthy | Gen. Counsel |
Exchange: OTCGREY
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.5935 |
| Price-to-Sales TTM: | 77.2211 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 650 |